 |
English
|
正體中文
|
简体中文
|
Items with full text/Total items : 12145/12927 (94%)
Visitors : 907618
Online Users : 945
|
|
|
Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/11134
|
| Title: | The clinical impact of the novel tumor marker DR-70 in unresectable gastric cancer patients |
| Authors: | Hung, YP;Chen, MH;Lin, JS;Hsiao, CF;Shan, YS;Chen, YC;Chen, LT;Liu, TW;Li, CP;Chao, Y |
| Contributors: | Institute of Population Health Sciences;National Institute of Cancer Research |
| Abstract: | Background: Gastric cancer tumor markers, such as carcinoembryonic antigen (CEA) and cancer antigen 19-9 (CA 19-9), have been applied in clinical practice to screen or monitor treatment responses. However, their sensitivity and specificity are unsatisfactory. Therefore, we assessed the novel tumor marker DR-70 and evaluated its performance in screening and response monitoring. Methods: The study included newly diagnosed patients with advanced gastric cancer from March 2012 to October 2015. We measured the DR-70, CEA, and CA 19-9 levels at the time of enrollment. The patients subsequently underwent chemotherapy. We followed-up the patients every 3 months; DR-70 levels and abdominal computed tomography scans were re-evaluated and repeated, respectively, at each follow-up. The correlation between treatment response and DR-70 level after chemotherapy was analyzed. The overall survival and progression-free survival rates were also evaluated. Results: A total of 51 patients with gastric cancer were enrolled. Most (82.4%) had metastatic disease. At enrollment, the sensitivity of DR-70 in our study group was 78.4%, compared with 52.9% and 43.1% for CEA and CA 19-9, respectively. When we used the three tumor markers together, the sensitivity increased to 80.4%. We observed a correlation between treatment response and DR-70 level after chemotherapy. No difference in either overall survival or progression-free survival was observed between the DR-70 positive and negative groups. However, a trend toward poorer overall survival was observed for the high DR-70 group, although this was not statistically significant. Conclusion: DR-70 is a powerful tool not only for screening unresectable gastric cancer but also for treatment response evaluation. |
| Date: | 2018-07 |
| Relation: | Journal of the Chinese Medical Association. 2018 Jul;81(7):593-598. |
| Link to: | http://dx.doi.org/10.1016/j.jcma.2018.01.009 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1726-4901&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:000435748700003 |
| Cited Times(Scopus): | https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85044986979 |
| Appears in Collections: | [蕭金福] 期刊論文
[陳立宗] 期刊論文
[劉滄梧] 期刊論文
|
Files in This Item:
| File |
Size | Format | |
|---|
| SCP85044986979.pdf | 1005Kb | Adobe PDF | 381 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
